Marina, N M, Smeland, S, Bielack, S S, Bernstein, M, Jovic, G, Krailo, M D, Hook, J M, Arndt, C, van den Berg, H, Brennan, B, Brichard, B, Brown, K L B, Butterfass-Bahloul, T, Calaminus, G, Daldrup-Link, H E, Eriksson, M, Gebhardt, M C, Gelderblom, H, Gerss, J, Goldsby, R, Goorin, A, Gorlick, R, Grier, H E, Hale, J P, Hall, K S, Hardes, J, Hawkins, D S, Helmke, K, Hogendoorn, P C W, Isakoff, M S, Janeway, K A, Jürgens, H, Kager, L, Kühne, T, Lau, C C, Leavey, P J, Lessnick, S L, Mascarenhas, L, Meyers, P A, Mottl, H, Nathrath, M, Papai, Z, Randall, R L, Reichardt, P, Renard, M, Safwat, A A, Schwartz, C L, Stevens, M C G, Strauss, S J, Teot, L, Werner, M, Sydes, M R & Whelan, J S 2016, ' Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOSan open-label, international, randomised controlled trial-1): an open-label, international, randomised controlled trial ', The Lancet Oncology, vol. 17, no. 10, pp. 1396-1408 . https://doi.org/10.1016/S1470-2045(16)30214-5